Mark Caulfield

Barts and the London, Queen Mary's School of Medicine, London, UK

Show Academic Trajectory

Ego Network

D-Core

Research Interests

Author Statistics

Experience

Education

Bio

None

Papers23 papers

Sort

By YearBy Citation

Monotherapy versus dual therapy for the initial treatment of hypertension (PATHWAY-1): a randomised double-blind controlled trial: figure 1

Thomas M Macdonald,Bryan Williams,Mark J Caulfield,J Kennedy Cruickshank,Gordon T Mcinnes,Peter S Sever,David J Webb,Isla S Mackenzie,Jackie Salsbury,Steve Morant,Ian Ford,M J Brown

BMJ Open, (2015)

Bibtex

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3)

M J Brown, Bryan Williams, Steve Morant,David J Webb,Mark J Caulfield,J Kennedy Cruickshank,Ian Ford,Gordon T Mcinnes,Peter S Sever, Jackie Salsbury,Isla S Mackenzie,Sandosh Padmanabhan

Journal of Psychiatric and Mental Health Nursing, (2015)

Bibtex

Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trial

M J Brown,Bryan L Williams,Steve Morant,David J Webb,Mark J Caulfield,J Kennedy Cruickshank,Ian Ford,Gordon T Mcinnes,Peter S Sever,Jackie Salsbury,Isla S Mackenzie,Sandosh Padmanabhan

Journal of Psychiatric and Mental Health Nursing, (2015)

Cited by2Bibtex

Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

Bryan Williams,Thomas M Macdonald,Steve Morant,David J Webb,Peter S Sever,Gordon T Mcinnes,Ian Ford,J Kennedy Cruickshank,Mark J Caulfield,Jackie Salsbury,Isla S Mackenzie,Sandosh Padmanabhan

The Lancet, (2015)

Cited by339Bibtex

Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension

B R Williams,Thomas M Macdonald,Mark J Caulfield,J Kennedy Cruickshank,Gordon T Mcinnes,Peter S Sever,David J Webb,Jackie Salsbury,Steve Morant,Ian Ford,M J Brown

BMJ OPEN, no. 8.0 (2015)

Cited by8Bibtex

Comparison of single and combination diuretics on glucose tolerance (PATHWAY-3): protocol for a randomised double-blind trial in patients with essential hypertension

M J Brown,Bryan Williams,Thomas M Macdonald,Mark J Caulfield,J Kennedy Cruickshank,Gordon T Mcinnes,Peter S Sever,David J Webb,Jackie Salsbury,Steve Morant,Ian Ford

BMJ OPEN, no. 8.0 (2015)

Cited by4Bibtex

2013 ESH/ESC Guidelines for the management of arterial hypertension

Authors,Task Force Members,Giuseppe Mancia,R Fagard,Krzysztof Narkiewicz,Josep Redon,Alberto Zanchetti,Michael Bohm, Thierry Christiaens,Renata Cifkova,Guy De Backer,Anna F Dominiczak

European Heart Journal, (2013)

Cited by39Bibtex

Proportion of patients with previously uncontrolled hypertension who achieve target blood pressure through participation in the BHS's prevention and treatment of hypertension with algorithm based therapy (PATHWAY) trials

Michael J I Brown,Mark J Caulfield, K Cruickshank,Thomas M Macdonald,Gordon T Mcinnes,Peter S Sever,David J Webb,B C Williams,Ian Ford

Journal of Human Hypertension, (2012)

Bibtex

Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy

Harshal Deshmukh,Helen M Colhoun,Toby Johnson, Paul Mckeigue,D John Betteridge,Paul N Durrington, J H Fuller,Shona J Livingstone,Valentine Charltonmenys, A Neil,Neil R Poulter,Peter S Sever

(2012)

Bibtex

Ethnic Differences in Blood Pressure Response to First and Second-Line Antihypertensive Therapies in Patients Randomized in the ASCOT Trial

Ajay K. Gupta,Neil R. Poulter,Joanna Dobson,Sandra Eldridge,Francesco P. Cappuccio,Mark Caulfield,David Collier,J. Kennedy Cruickshank,Peter S. Sever,Gene Feder

AMERICAN JOURNAL OF HYPERTENSION, no. 9.0 (2010): 1023-1030

Cited by59Bibtex

Europejskie zalecenia dotyczące leczenia nadciśnienia tętniczego: stanowisko Europejskiego Towarzystwa Nadciśnienia Tętniczego 2009

Giuseppe Mancia,Stéphane Laurent,Enrico Agabiti-Rosei,Ettore Ambrosioni,Michel Burnier,Mark J. Caulfield,Renata Cifkova,Denis Clément,Antonio Coca,Anna Dominiczak,Serap Erdine,Robert Fagard

Arterial Hypertension, no. 1 (2010): 1-47

Bibtex

Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients--an Anglo-Scandinavian cardiac outcomes trial substudy

Dolan Eamon,Stanton Alice V,Thom Simon,Caulfield Mark,Atkins Neil,McInnes Gordon,Collier David,Dicker Patrick,O'Brien Eoin, Null Null

Journal of hypertension, no. 4 (2009): 876-885

Cited by61WOSBibtex

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes

Ostergren Jan,Poulter Neil R,Sever Peter S,Dahlöf Björn,Wedel Hans,Beevers Gareth,Mark J Caulfield,Collins Rory,Kjeldsen Sverre E,Kristinsson Arni,McInnes Gordon T,Mehlsen Jesper

Journal of hypertension, no. 11 (2008): 2103-2111

Cited by102WOSBibtex

Abstract 4152: Did Older or Younger Patients Benefit More from Amlodipine based vs Atenolol based Therapy in ASCOT-BPLA

D J Collier,Mark J Caulfield,Neil R Poulter,Bjorn Dahlof,Hans Wedel,Peter S Sever

Circulation, (2006)

Bibtex

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial

Sever Peter,Dahlöf Björn,Poulter Neil,Wedel Hans,Beevers Gareth,Caulfield Mark,Collins Rory,Kjeldsen Sverre,Kristinsson Arni,McInnes Gordon,Mehlsen Jesper,Nieminem Markku

European Heart Journal, no. 24 (2006)

Cited by170WOSBibtex

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

Dahlöf Björn,Sever Peter S,Poulter Neil R,Wedel Hans,Beevers D Gareth,Caulfield Mark,Collins Rory,Kjeldsen Sverre E,Kristinsson Arni,McInnes Gordon T,Mehlsen Jesper,Nieminen Markku

Lancet (London, England), no. 9489 (2005): 895-906

Cited by3539WOSEIBibtex

Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA)

Neil R Poulter,Hans Wedel,Björn Dahlöf,Peter S Sever,D Gareth Beevers,Mark J Caulfield,Sverre E Kjeldsen,Arni Kristinsson,Gordon T McInnes,Jesper Mehlsen,Markku S Nieminen,Eoin O'Brien

ACC Current Journal Review, no. 12 (2005): 18-913

Cited by450EIBibtex

D G Beevers,Mark J Caulfield,Rory Collins,Bjorn Dahlof,Sverre E Kjeldsen,Arni Kristinsson,Gordon T Mcinnes,Jesper Mehlsen,Markku S Nieminen, E Obrien,Jan Ostergren,Neil R Poulter

(2005)

Bibtex

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial - Lipid Lowering rm (ASCOT-LLA): a multi

Peter S Sever,Bjorn Dahlof,Neil R Poulter,Hans Wedel,G Beevers,Mark J Caulfield,Rory Collins,Sverre E Kjeldsen,Arni Kristinsson,Gordon T Mcinnes,Jesper Mehlsen,Markku S Nieminen

(2003)

Bibtex

Peter S Sever,Björn Dahlöf,Prof Neil R Poulter,Hans Wedel,Gareth Beevers,Mark J Caulfield,Rory Collins,Sverre E Kjeldsen,Arni Kristinsson,Gordon T McInnes,Jesper Mehlsen,Markku S Nieminen

The Lancet, no. 9364 (2003): 43-60

Cited by4786EIWOSBibtex

View All

Base Info Papers Patents Projects